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220was completed in 4 patients with incessant VT: before
the diagnosis of TB in 1 patient and during anti-TB
treatment in the remaining 3 patients. Patients were
followed up at 1, 3, and 6 months after the initiation of
anti-TB treatment and when clinically warranted. The
response was assessed after the intensive phase of
anti-TB treatment in terms of clinical improvement,
change in ejection fraction by echocardiography, and
change in 18-ﬂuorodexoyglucose uptake by PET/CT.
There was signiﬁcant improvement in ejection
fraction (mean 46.7  14.4% to 50.8  16.1%; p ¼
0.009). All patients but 1 became free of VT. In a
follow-up PET/CT (n ¼ 11), abnormal metabolic ac-
tivity resolved completely in the myocardium in 4
patients and in the lymph nodes in 9 patients (Ta-
ble 1). There were no deaths.
Our observations suggest that TB can present as
idiopathic VT or unexplained ventricular dysfunction;
patients may not have constitutional symptoms.
Biopsy targeting ﬂuorodeoxyglucose-avid lymph
nodes rather than endomyocardial biopsy is more
useful inmaking a clinical diagnosis. It may be prudent
to investigate all patients with unexplained VT or left
ventricular dysfunction and lymphadenopathy for
myocardial TB, especially in those areas where the
prevalence of TB is high. By subjecting the biopsy
specimen to mycobacterial culture, TB polymerase
chain reaction and histopathologic examination will
help in distinguishing between TB and sarcoidosis—
another granulomatous condition that may present in
a similar fashion (4). This report serves to highlight the
fact that myocardial TB may be more common than
believed. Early diagnosis is important to prevent
morbidity and mortality.Alladi Mohan, MD
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48–55.Increased Mortality by
Digoxin in Patients With
Atrial Fibrillation?In the TREAT-AF (Retrospective Evaluation and
Assessment of Therapies in AF) study (1), the effect of
digoxin on overall mortality in patients with incident
atrial ﬁbrillation (AF) was studied. In this observa-
tional study, after adjustment for potential con-
founders with the Cox proportional hazards model
and propensity score analyses, digoxin was associ-
ated with an increased risk (21% to 24%) of death. The
investigators extensively discussed the potential
limitations of their study, but I have 2 questions
about the design choices.
First, the investigators stated that patients were
placed in the digoxin group versus the reference
group on the basis of use of digoxin within the ﬁrst
90 days after the diagnosis of AF. Digoxin is the ﬁrst
choice for therapy in patients with AF complicated by
heart failure and the second choice in patients whose
ﬁrst choices for treatment of AF, beta-blockers and
calcium channel antagonists, are not effective
enough. When only the ﬁrst 90 days are used for
exposure classiﬁcation, there may be a substantial
misclassiﬁcation of digoxin in both the digoxin group
and the reference group. The fact that the medication
possession ratio of digoxin was only calculated for the
digoxin group does not take into account such
misclassiﬁcation.
Second, the investigators stated that they
adjusted for the medication possession ratio in the
multivariate Cox analysis. I do not understand this:
how can you adjust for a variable that is zero in
all patients in the reference group and a certain
number between zero and one in the digoxin group?
I believe the appropriate analysis would be to
stratify the digoxin group with different medication
possession ratios and compare these with the refer-
ence group.
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Patients With Atrial Fibrillation?Dr. de Boer brings up some important design con-
siderations regarding our analysis of the TREAT-AF
(Retrospective Evaluation and Assessment of Ther-
apies in AF) study (1). He correctly argues that there
can be misclassiﬁcation of digoxin exposure in our
design. Our observational study was designed as an
intention-to-treat analysis, comparing the strategies
of use and nonuse of digoxin as initial or early
therapy in patients with newly diagnosed atrial
ﬁbrillation (AF) (1). Although we found that 80% of
patients in the digoxin arm were still on therapy
at 1 year, there is a strong possibility of digoxin
exposure in the control arm after 90 days. How-
ever, we believe this would not represent “mis-
classiﬁcation” in an intention-to-treat design but
rather crossover of therapy. Generally, crossover
would bias toward the null and therefore would not
likely account for the observed difference in
outcomes.
Therapy crossover is common in management of
AF and complicates analysis and interpretation of
randomized trials. Crossover may be motivated by
observed and unobserved confounders, which can
further complicate analysis and may in part explain
the seemingly incongruent results of 2 secondary
analyses of digoxin using the same AFFIRM (AF
Follow-Up Investigation of Rhythm Management)
trial data set (2,3). Separating patients into exposed
and unexposed blocks of person-time without
adjusting for time-varying confounders could exag-
gerate treatment effect (or harm) (4). On the other
hand, contemporary approaches such as marginal
structural models that incorporate time-varying datacan bias toward the null from overadjustment or
model misspeciﬁcation (5).
For these reasons, we elected to study a new dis-
ease cohort using an intention-to-treat design that
evaluated digoxin as an initial treatment strategy.
Our decision to adjust for adherence rather than to
stratify was to account for variation in adherence in
the overall point estimate. We agree that further work
to explore the heterogeneity of treatment effects
across strata of adherence and time course of therapy
would be valuable and complementary.*Mintu P. Turakhia, MD, MAS
Paul A. Heidenreich, MD, MS
*Veterans Affairs Palo Alto Health Care System
Stanford University School of Medicine
3801 Miranda Avenue, 111C
Palo Alto, California 94304
E-mail: mintu@stanford.edu
http://dx.doi.org/10.1016/j.jacc.2014.10.032
REF ER ENCES
1. Turakhia MP, Santangeli P, Winkelmayer WC, et al. increased mortality
associated with digoxin in contemporary patients with atrial ﬁbrillation.
J Am Coll Cardiol 2014;64:660–8.
2. Whitbeck MG, Charnigo RJ, Khairy P, et al. Increased mortality among
patients taking digoxin—analysis from the AFFIRM study. Eur Heart J 2013;34:
1481–8.
3. Gheorghiade M, Fonarow GC, Van Veldhuisen DJ, et al. Lack of evidence of
increased mortality among patients with atrial ﬁbrillation taking digoxin:
ﬁndings from post hoc propensity-matched analysis of the AFFIRM trial. Eur
Heart J 2013;34:1489–97.
4. Murphy SA. When ’digoxin use’ is not the same as “digoxin use”: lessons
from the AFFIRM trial. Eur Heart J 2013;34:1465–7.
5. Schisterman EF, Cole SR, Platt RW. Overadjustment bias and unnecessary
adjustment in epidemiologic studies. Epidemiology 2009;20:488–95.Patent Foramen Ovale
and Paradoxical
Systemic Embolism
Can We Determine High-Risk Characteristics
by Echocardiography?We read with interest the review paper on paradoxi-
cal embolism by Windecker et al. (1). It was sug-
gested, on the basis of available evidence from
published reports, that device closure of patent
foramen ovale (PFO) should be considered in patients
with ﬁrst-time cryptogenic stroke, particularly in
those with high-risk criteria, such as presence of
an atrial septal aneurysm (ASA), large PFO, Eusta-
chian valve, or Chiari network. The viewpoints of
